AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 302 min read$GLUE

Janku Filip sold $138K of GLUE

Janku Filip (Chief Medical Officer) sold 6,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $22.95 ($0.14M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Janku Filip
Published Jun 30, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GLUE
Neutral
high confidence
Mentioned
$GLUE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

The newest disclosed fact is the June 29 open-market sale of 6,000 shares by the CMO at $22.95, filed June 30, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and small dollar amount relative to typical biotech flows imply limited trading edge.

03

What to watch

The filing doesn’t disclose reasons for sale; also, the post-sale holdings (59,992 shares) suggest the insider remains materially invested.

Relevance 3/10Novelty 3/10Timing: filed June 30 after the June 29 sale

Background

This is an SEC Form 4 insider transaction for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralHigh confidence
Context

Monte Rosa Therapeutics’ CMO Janku Filip sold 6,000 shares at $22.95 under a pre-arranged 10b5-1 plan, totaling $137.7K.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and small.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

Sector

No sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely mechanical (tax/portfolio rebalancing) and may not reflect bearish expectations.

Key entities

  • equity issuer
    GLUE

    Monte Rosa Therapeutics, Inc.; subject of the insider sale disclosure.

  • insider
    Janku Filip

    Chief Medical Officer who executed the 10b5-1 sale.

Read at source← All news

Related articles

AUG 6
$GLUEMed

Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029

Monte Rosa Therapeutics reported a Q2 2026 net loss of $43.4M, with collaboration revenue of $9.0M. Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0M as of June 30, 2026, supporting operations into 2029. R&D and G&A rose year over year. The company advanced MRT-8102 and other programs, including Novartis-activated MRT-6160 Phase 2.

tradingview.com1 min
AUG 6
$GLUEMed

Monte Rosa Therapeutics, Inc. (GLUE): Results of Operations and Financial Condition

Monte Rosa Therapeutics, Inc. (GLUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 glue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout

SEC EDGAR 8-K6 min
JUL 31
$GLUEMed

Why is Monte Rosa Therapeutics stock plunging today?

Amazon shares rally as cloud growth surges and spending outlook climbs Investing.com -- Monte Rosa Therapeutics shares plummeted nearly 29.9% in pre-open trading today, trading at $15.90, after Novo Nordisk disclosed that its Phase 3 ZEUS cardiovascular outcomes trial for ziltivekimab — an IL-6 pathway inhibitor — failed to demonstrate a statistically meaningful reduction in major adverse cardiovascular events versus placebo in patients with atherosclerotic cardiovascular disease, chronic...

investing.com4 min
JUN 5
$GLUEMedAI 9/10

Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy

Monte Rosa Therapeutics (GLUE) reported May 7 progress in its clinical pipeline, with three programs moving toward Phase 2. MRT-8102 (NEK7) showed CRP reductions in early trials and plans multiple Phase 2 starts in H2 2026. MRT-6160 (VAV1) with Novartis and MRT-2359 (GSPT1) in mCRPC also advance, with a Phase 2 combo with apalutamide planned for Q3 2026. The company reported $671M cash, expected to fund operations into 2029.

finance.yahoo.com4 min
MAY 29
$GLUEMedAI 9/10

Molecule glue drugs shake up cancer care, draw big money

Revolution Medicines (RevMed) said its daraxonrasib doubled survival in aggressive pancreatic cancer, from 6.7 to 13.2 months, with final-stage results due at a Chicago medical conference. The outcome has spurred dealmaking and development of “molecular glue” drugs targeting “undruggable” proteins. RevMed’s market cap neared $33B; it plans FDA filing and an ultrafast review, with projected $7B annual sales by 2032.

economictimes.indiatimes.com6 min